Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | FECH | P22830 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634324 | 0.86 | PLK1 (0.39) | MMP1PLK1METNQO2FECH | |
| SCHEMBL1635650 | 0.83 | PLK1 (0.38) | MMP1PLK1METNQO2FECH | |
| SCHEMBL1635654 | 0.83 | PLK1 (0.38) | MMP1PLK1METNQO2FECH | |
| SCHEMBL1636203 | 0.82 | PLK1 (0.57) | MMP1PLK1METNQO2FECH | |
| SCHEMBL1634069 | 0.80 | PTGS1 (0.39) | MMP1PLK1METNQO2FECH | |
| SCHEMBL1634065 | 0.80 | PTGS1 (0.39) | MMP1PLK1METNQO2FECH | |
| SCHEMBL3235916 | 0.79 | PLK1 (0.44) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL3235926 | 0.79 | PLK1 (0.44) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL1635763 | 0.79 | ABCG2 (0.38) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL1635766 | 0.79 | ABCG2 (0.38) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138832-A1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-03-08 | — | — | EP | claimed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | claimed |
| EP-3138832-A1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | MMP1 2013/4885PLK1 430/4885MET 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.